Stocks · News reference
Adagene and Incyte have dosed the first patient in a Phase 1 clinical trial evaluating the combination of muzastotug and Incyte's bispecific antibody INCA33890 for patients with microsatellite stable colorectal cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Incyte (NASDAQ:INCY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Incyte Corporation announced its financial results for the third quarter of 2026 and provided updates on its business operations.
Filed: 2026-10-29 AccNo: 0000879169-26-000063 Size: 630 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits